ALKERMES | ALKS - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
AbbVie USD 10.27B 538M 2026-03
Acadia Pharmaceuticals USD 272.68M 6.08M 2026-03
ALKERMES USD 1.75B 1.43B 2026-03
Amgen USD 4.78B 1.12B 2026-03
Biogen USD 1.96B 69.6M 2026-03
BioMarin Pharmaceutical USD 636.56M 39.61M 2026-03
Bristol-Myers Squibb USD 20.07B 11.77B 2026-03
Coherus Biosciences USD 51.83M 2.48M 2025-12
Eli Lilly USD 10.02B 285M 2026-03
Gilead Sciences USD 23.52B 18.55B 2026-03
Heron Therapeutics USD 40.55M 1.46M 2025-12
Ionis Pharmaceuticals USD 364M 54M 2026-03
J&J USD 17.44B 1.53B 2026-03
Malin Corporation EUR 1.1M 400K 2024-12
Merck USD 18.17B 8.01B 2026-03
Minerva Neurosciences USD 4.52M 155.46K 2024-12
Nektar Therapeutics USD 40.9M 44.19M 2025-12
Neurocrine Biosciences USD 599.9M 22.3M 2026-03
Otsuka Holdings JPY 512.13B 70.77B 2026-03
Ovoca Bio EUR 1.16M 4.48M 2025-06
Pfizer USD 90.1B 77.19B 2026-03
Regeneron Pharmaceuticals USD 31.42B 28.44B 2026-03
Vertex Pharmaceuticals USD 1.85B 78.6M 2026-03